COVID-19 outbreak and increased risk of amblyopia and epidemic myopia: Insights from EUROCOVCAT group

Toro, Mario Damiano; Bremond-Gignac, Dominique; Brézin, Antoine Pierre; Cummings, Arthur Bernard; Kemer, Ozlem Evren; Kermani, Omid; Malyugin, Boris Edvard; Prieto, Isabel; Teus, Miguel Angel; Tognetto, Daniele; Zweifel, Sandrine; Rejdak, Robert

Abstract: The most common cause of vision impairment in children is amblyopia. It is defined as impaired visual acuity in one or both eyes that is present with no demonstrable abnormality of the visual pathway and is not immediately resolved by wearing glasses. After the World Health Organization (WHO) recognized COVID-19 as a global pandemic on March 11, 2020, widespread changes and restrictions to social and sanitary practices have presented significant issues in access to eye care during the COVID-19 pandemic. A reduction of more than 80% in pediatric eye care volume up to its total cessation has been observed in different departments. In this scenario, reduced or absent eyesight, due to delay in timely treatment of amblyopic conditions, could create major, long-lasting effects on all aspects of life, including daily personal activities, interacting with the community, school and work opportunities and the ability to access public services. Processes coming out of lockdown should be gradually easing restrictions giving priority to ophthalmology and eye care facilities so that amblyopia does not remain unattended and irreversible as in adults due to lack of timely treatments. If not reversible, this process could lead to a dramatic increase in disability and unsustainable social costs for many governments.

DOI: https://doi.org/10.1177/11206721211053175
COVID-19 outbreak and increased risk of amblyopia and epidemic myopia: Insights from EUROCOVCAT group

Mario Damiano Toro1,2, Dominique Bremond-Gignac3,4, Antoine Pierre Brézin5, Arthur Bernard Cummings6, Ozlem Evren Kemer7, Omid Kermani8, Boris Edvard Malyugin9,10, Isabel Prieto11, Miguel Angel Teus12, Daniele Tognetto13, Sandrine Zweifel2 and Robert Rejdak1

Abstract
The most common cause of vision impairment in children is amblyopia. It is defined as impaired visual acuity in one or both eyes that is present with no demonstrable abnormality of the visual pathway and is not immediately resolved by wearing glasses. After the World Health Organization (WHO) recognized COVID-19 as a global pandemic on March 11, 2020, widespread changes and restrictions to social and sanitary practices have presented significant issues in access to eye care during the COVID-19 pandemic. A reduction of more than 80% in pediatric eye care volume up to its total cessation has been observed in different departments. In this scenario, reduced or absent eyesight, due to delay in timely treatment of amblyopic conditions, could create major, long-lasting effects on all aspects of life, including daily personal activities, interacting with the community, school and work opportunities and the ability to access public services. Processes coming out of lockdown should be gradually easing restrictions giving priority to ophthalmology and eye care facilities so that amblyopia does not remain unattended and irreversible as in adults due to lack of timely treatments. If not reversible, this process could lead to a dramatic increase in disability and unsustainable social costs for many governments.

Keywords
COVID-19 pandemic, pediatric-eye care, amblyopia, irreversible blindness, ophthalmology, visual impairment

Date received: 10 May 2021; accepted 23 September 2021

1Department of General and Pediatric Ophthalmology, Medical University of Lublin, Lublin, Poland
2Department of Ophthalmology, University Hospital of Zurich, Zurich, Switzerland
3University Hospital Necker Enfants Malades, APHP, Paris, France
4INSERM 1138, Team 17, Paris Sorbonne University, Cordeliers, Paris, France
5Université de Paris, Hôpital Cochin, APHP, Paris, France
6Wellington Eye Clinic, Dublin, Ireland
7University of Health Sciences, Ankara City Hospital, Ankara, Turkey
8Augenklíník am Neumarkt Schildergasse 107 – 109, Köln, Germany
9Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russian Federation
10A. Yevdokimov Moscow State University of Medicine and Dentistry, Russian Federation
11Fernando Fonseca Hospital, Amadora, Portugal
12University of Alcalá, Madrid, Spain
13University Eye Clinic, Trieste, Italy

Corresponding author:
Mario Damiano Toro, Department of General and Pediatric Ophthalmology, Medical University of Lublin, ul. Chmielna 1, Lublin 20-079, Poland.
Email: toro.mario@email.it
**What is known**

- Amblyopia is the most common causes of vision problems in children and it is estimated at 1–6% in different areas.
- It develops during early childhood when the visual system is vulnerable to changes in visual stimulation and it remains as permanent visual defect into adulthood if left untreated.

**What is new**

- Due to the COVID-19 pandemic, a dramatic reduction in the access to pediatric-eye-care has been observed.
- If not reversible, a delay in timely treatment of amblyopic conditions could lead to an increase in disability and unsustainable social costs for many Governments.

After the World Health Organization (WHO) recognized COVID-19 as a global pandemic on March 11, 2020, widespread changes and restrictions to social and sanitary practices have presented significant issues in access to eye-care during the COVID-19 pandemic. Several national ophthalmology societies have sought to defer any treatment other than urgent or emergency care to contain human to human viral transmission. Thus, to deal with rising cases of COVID-19, the outbreak practically brought all clinical activity to a standstill for several-weeks and an increasing need to prioritize access to eye care while broadly maintaining SARS-CoV-2 infection control. This poses many risks, delays or suspends non-essential outpatient visits and elective surgical procedures. Patient visits and encounters have significantly decreased in many subspecialties, with a loss of more than 81% of annual patient volume for a two-week period in March and April 2020 compared to the corresponding period in 2019 in eye care. In our experience, during the first COVID-19 lockdown a reduction of more than 80% in pediatric eye care volume up to its total cessation has been observed in many of our departments. If reconfirmed, this reduction in volume in pediatric eye care is second only to that experienced in cataract surgery volumes, as a consequence of the need to prioritize emergency treatment.

To date, no clear European data is available yet on the impact of COVID-19 on pediatric eye care in different National Health Systems. Thus, it is of paramount importance to assess the impact of lockdown on ophthalmological care and its future adverse consequences in terms of disability and access to vision-saving cures for many pediatric patients. To address this challenge, we have brought together EUROCOVCAT (European COVID-19 Cataract Group), a group of ophthalmic surgeons, specialists including pediatric ophthalmologists and experts from 12 European countries, to discuss how to resume practicing ophthalmology in the safest and most efficient manner, and reduce the risk of eye diseases such as amblyopia. The group is also creating awareness among national governments to allow ophthalmology practices to remain open during lockdown to minimize unnecessary sight-loss, particularly in vulnerable children in visual development. EUROCOVCAT has organized conferences and calls sharing fruitful experiences and perspectives on the current context. An in-depth analysis of the current situation in pediatric eye care has been merged with the updated literature and available recommendations from scientific ophthalmic societies and healthcare institutions. Here we summarize some recommendations practical hints and key steps for the reorganization of pediatric care management and reorganization during the time of COVID-19, merging the experiences of the European COVID-19 Cataract Group (EUROCOVCAT) including the most update published literature and guidelines. Additionally, new perspective and solutions are provided to the health providers to facilitate and coordinate their cooperation with in- and out-patient clinics.

Bangerter has defined amblyopia as an under-functioning caused by deprivation. Accordingly, one eye remains impaired and sends altered signals to the brain. So, the patient uses the ‘good eye’ or normal eye for all activities. This affects depth perception or stereopsis that require healthy functioning in both eyes. Amblyopia presents low visual acuity without any apparent abnormality of the visual pathway in one or both eyes and cannot be immediately resolved by wearing glasses. The term is used most frequently to refer to the unilateral condition, although amblyopia may be bilateral. Refractive correction cannot reverse and cure the disease in adults, as after the age of about 10 years, it cannot be fully reversed. Amblyopia is categorized into three types: strabismus (squint), stimulus deprivation such as cataract or ptosis, and anisometropia.

Amblyopia develops rapidly during early childhood (birth to 8–10 years of age) when there is inadequate visual stimulation in one eye as optic signals do not properly reach the brain. It remains a reversible condition and varies in incidence based on regions and age groups. In children, impaired vision from birth or in early childhood can have a negative effect on their growth and development if left untreated or not treated in a timely manner. Indeed, a low vision in childhood may lead to inadequate emotional and social development of the child with severe adverse long-term social, psychological, and financial consequences for the families. Indeed, untreated amblyopia rarely gets resolved spontaneously. About one-fourth of the population of people with amblyopia have visual acuity in the affected eye worse than 20/
There is significant neural plasticity in the amblyopic brain beyond the critical period. Baseline and clinical factors such as the initial visual acuity, type of amblyopia, treatment initiation age, the efficacy of the treatment modality and patient’s compliance are key factors affecting the outcome. Hence, appropriate timely treatment during the critical period mitigates adverse outcomes later. Although many ophthalmological treatments are elective with scheduled visits or surgeries and may be postponed without any major impact on public health, the pediatric treatments should not be postponed as prolonged vision loss during formative periods is irreversible.

Amblyopia may remain asymptomatic and undetected for years to the parents or the impacted child, because they typically have good visual acuity in the normal eye. Therefore, during the preschool period, many children remain undiagnosed because their eyes appear normal initially until school admission. Accordingly, it is readily predictable that any delay or suspension in essential pediatric eye interventions or procedures may cause significant and rapid vision impairment to irreversible vision loss in younger generations.

Some authors have already highlighted the silent impact of increasing usage of digital devices on children’s eye health during the ongoing COVID-19 pandemic. Before the COVID-19 outbreak children were growing up in a highly visually demanding world where electronic devices, e-readers, tablets, video games, and the ubiquitous mobile phone were exploited for entertainment and leisure. Increased digital screen time, near homework, and limited outdoor activities were found to be associated with the onset and progression of myopia, and can potentially be worsened during and beyond the COVID-19 pandemic outbreak. Additionally, the diffusion of e-learning has recently increased the use of electronic devices as tools for long-term daily use, leading to an exponential increase in digital eye strain (DES), making it an emerging public health problem with a reported prevalence of more than 50% among children in the COVID era.

Jayadev et al. have reported that approximately 80% of outpatient visits in the pediatric ophthalmology department in March and April 2020 (at the start of the lockdown) were for refractive errors, of which 79% were for myopia. Nowadays with no definitive end in sight for the pandemic, we are potentially facing scenario of ‘quarantine myopia’ which is potentially explosive. There are predictions of a worsening of the myopic epidemic worldwide and is estimated that over 50% of the world’s population will have myopia by 2050. Recently, a prospective study designed to investigate the refractive changes and prevalence of myopia in school-aged children during the COVID-19 home confinement in 123,535 children aged 6 to 13 years, has reported a significant myopic shift for children aged 6 to 8 years of approximately −0.3 diopters in China. These results are consistent with the data of another large-scale intervention study with 12-month follow-up on myopia development among 1,001,749 schoolchildren of 1305 elementary and high schools. Here, myopia increased approximately 1.5 times from −0.23 D during the pre-COVID-19 to −0.343 D during the post-COVID-19 period. Moreover, even if data are still controversial, besides myopic progression, accommodative dysfunction in children may be also on the rise due to digital device usage. Accommodation spasm and sudden onset esotropia are important consequences. The former presents with an acute, rapid increase in myopia and requires dynamic, cycloplegic retinoscopy, and a comprehensive assessment of the binocular visual field. Receded near the point of convergence, large near exophoria, reduced near the point of accommodation, and lag of accommodation greater than +1.25 diopter sphere demand further assessment for non-strabismic binocular vision dysfunction. Vision therapy may play also a significant role in managing these anomalies.

With this information in mind, and to avoid any increase in the incidence of amblyopia, some authors have already proposed evidence-based recommendations on how to adequately evaluate children during the amblyopic period while reducing COVID-19 transmission. We believe that the following recommendations should always be implemented in all cases of suspected pediatric amblyopia or myopia (Figure 1):

- If the child has already been screened and a diagnosis of amblyopia has been made, the treatment should be continued and the appointment to monitor the ametropia may be postponed without any additional risk;
- If the child has not been seen and a decreased visual acuity or strabismus is suspected, he/she should be seen to eliminate an organic cause or the risk of amblyopia, especially if under six years of age;
- If strabismus has already been diagnosed, an alternating or unilateral occlusion depending on the case should be started and maintained according the last ophthalmological consultation and until the next one; this treatment renewing may be carried out via telemedicine.

In any case, all children should be seen urgently to eliminate an organic cause (e.g. retinoblastoma, tumors, congenital glaucoma, infection, traumatic lesion of ocular adnexa.) if under two years of age or with an acute onset of strabismus or recent nystagmus or suspicious/obvious organic problem (leukocoria, buphthalmos, megalocornea, tearing, photophobia, red and/or painful eye, or trauma).

So far, we have limited data to accurately predict the future course of the COVID-19 pandemic. Even though many governments have already started easing the
current stringent lockdown measures, the current phase may last several months. Additionally, the diffusion of vaccines could prove beneficial in conditioning the return to normal life and provide effective responses to a potential COVID-19 resurgence. If pediatric patients are not treated in a timely manner, limited healthcare facilities might be overburdened with a large number of cases not being attended currently due to lockdown and eye care facilities being converted into corona wards/hospitals in Europe.

In this scenario, reduced or absent eyesight caused by the delay in timely treatment of amblyopic conditions could create major and long-lasting effects on all aspects of life and affects daily personal activities, such as interacting with the community, school and work opportunities and the ability to access public services. Amblyopia could prove costly and serious in the long run if patients are not attended immediately, especially in the vulnerable young age of up to 8 years, when cortical and optical nerves connecting the brain and the abnormal eye develop completely. If not reversed, the limited access to sight-saving cures for many pediatric patients could lead to harmful consequences in terms of even permanent disability in younger generations. Therefore, achieving a delicate balance between infection control and the supply of ophthalmology services to properly diagnose and treat childhood amblyopia is strongly recommended and suggested to avoid unsustainable social costs for many health care systems. Processes coming out of lockdown should be gradually easing restrictions on priority on eye care facilities (hospital/clinics) so that amblyopia does not remain unattended and irreversible as in adults due to lack of timely treatments. Adult low vision leads to a costly visual impairment reducing access to professional activity. Additionally, as eye health care providers, we need to promptly identify those children, if necessary, using telemedicine, who are at a higher risk of DES and progression of myopia to manage them appropriately. A public awareness campaign to improve safety measures, enhance early detection of DES, and promote prevention and screening measures in our young citizens is strongly needed. Presently, different screening tools are employed to assess the visual status of children. Vision screening for school-age children is important to detect uncorrected refractive errors. A WHO study has recommended that the screening of children for refractive errors should be integrated into school health programs and could be carried out by government and non-governmental organizations as well. Pediatric health care providers will need to screen and treat children and counsel their parents and/or other caregivers during well-child visits with an eye care practitioner for these new or worsened environmental threats. It is crucial to make teachers and parents aware that these practices can help to check the growing ill-effects of lockdown. Restriction of online classes with breaks in between sessions, promoting (permitted) outdoor activities, encouraging “family” time with non-gadget-based learning and entertainment are some measures that can be adopted. Favoring care to those of higher socioeconomic means, those with better access to care, and perhaps even of different race groups, is also a priority to make care more equitable.

In this scenario, telemedicine delivered both in an asynchronous or synchronous manner, may be a new tool able to deliver inpatient and outpatient pediatric care, educate pediatricians and patients’ families, and conduct medical research during the COVID-19 emergency. Indeed, with proper materials, technology, and staffing, telemedicine can be rapidly implemented to provide...
continued patient care during pandemic conditions.² It can also provide access to pediatric care to remote and underserved populations, considering its costs and sustainability, and the actual lack of technology infrastructure on a national scale. Ophthalmology relies heavily on objective assessments through examination techniques and investigations. Some techniques lend themselves to widely available smartphone and web-based technologies. These include visual acuity examinations, contrast testing, color vision testing, optical axial length and gaze photography. However, most of them are sophisticated examinations that must rely on specialized equipment with trained personnel to obtain standardized images. Nowadays, a multitude of smartphone extensions have been developed to obtain retinal imaging and are being systematically evaluated in some ocular diseases. However, for most of these applications, parameters around safety, efficacy, cybersecurity, privacy, and interoperability still need to be carefully tested before their approval.²⁶

**Abbreviations**
EUROCOVCAT European COVID-19 Cataract Group

**Acknowledgements**
The authors are grateful to Dr Faustino Vidal Aroca and other members of the EUROCOVCAT (European COVID-19 Cataract Group: Dr Ruth Lapid-Gortzak and Dr Kjell-Gunnar Gundersen for their suggestions and for providing critical analysis during the writing process of the manuscript. The work study has been supported by the “Foundation to support the development of Ophthalmology,” Lublin, Poland. The Foundation had no role in the interpretation of data or in the decision to publish the results.

**Author contributions**
Conceptualization: MDT.; writing—original draft preparation: MDT.; writing—review and editing: all authors; all authors have read and agreed to the published version of the manuscript.

**Declaration of conflicting interests**
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**
The author(s) received no financial support for the research, authorship and/or publication of this article.

**Institutional review board statement**
Not applicable.

**ORCID iDs**
Mario Damiano Toro https://orcid.org/0000-0001-7152-2613
Antoine Pierre Brézin https://orcid.org/0000-0001-8461-3119
Ozlem Evren Kemener https://orcid.org/0000-0001-9480-8470
Boris Edvard Malyugin https://orcid.org/0000-0001-5666-3493
Miguel Angel Teus https://orcid.org/0000-0002-3835-9882

**Supplemental material**
Supplemental material for this article is available online.

**References**
1. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report – 145. Geneva, https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200613-covid-19-sitrep-145.pdf?sfvrsn=b67c1de9_2 (2020, accessed 13 June 2020).
2. Romano MR, Montericcio A, Montalbano C, et al. Facing COVID-19 in ophthalmology department. Curr Eye Res 2020; 45: 653–658.
3. Dolar-Szczasny J, Toro MD, Dworzańska A, et al. Ocular involvement of SARS-CoV-2 in a polish cohort of COVID-19-positive patients. Int J Environ Res Public Health 2021; 18: 2916.
4. Cummings AB, Gildea C, Brézin AP, et al. Impact on refractive surgery due to increasing use of personal protection equipment: insights from EUROCOVCAT group. Eur J Ophthalmol 2021: 11206721211018641. doi:10.1177/11206721211018641.
5. Jørstad OK, Moe MC, Eriksen K, et al. Coronavirus disease 2019 (COVID-19) outbreak at the department of ophthalmology, Oslo university hospital, Norway. Acta Ophthalmol 2020; 98: e388–e389.
6. Ferrara M, Romano V, Steel DH, et al. Reshaping ophthalmology training after COVID-19 pandemic. Eye (London) 2020; 34: 2089–2097.
7. dell’Omo R, Filippelli M, Semeraro F, et al. Effects of the first month of lockdown for COVID-19 in Italy: a preliminary analysis on the eyecare system from six centers. Eur J Ophthalmol 2020; 1120672120953074. doi:10.1177/11206721211002442.
8. Bajka A, Wiest MRJ, Hamann T, et al. Assessment of patients’ confidence regarding a new triage concept in a medical retina clinic during the first COVID-19 outbreak. Int J Environ Res Public Health 2021; 18: 15846.
9. Tognetto D, Brézin AP, Cummings AB, et al. Rethinking elective cataract surgery diagnostics, assessments, and tools after the COVID-19 pandemic experience and beyond: insights from the EUROCOVCAT group. Diagnostics 2020; 10: E1035.
10. Carnevali A, Giannaccare G, Gatti V, et al. Intravitreal injections during COVID-19 outbreak: real-world experience from an Italian tertiary referral center. Eur J Ophthalmol 2021; 31: 10–12.
11. Borrelli E, Grosso D, Vella G, et al. Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let’s be ready for a plausible “rebound effect”. Graefes Arch Clin Exp Ophthalmol 2020; 258, 2655–2660.
12. Elfalah M, AlRyalat SA, Toro MD, et al. Delayed intravitreal anti-VEGF therapy for patients during the COVID-19 lockdown: an ethical endeavor. Clin Ophthalmol 2021; 15: 661–669.
13. Arruabarrena C, Toro MD, Onen M, et al. Impact on visual acuity in neovascular age related macular degeneration (nAMD) in Europe due to COVID-19 pandemic lockdown. J Clin Med 2021; 10: 3281.
14. Analysis: Ophthalmology Lost More Patient Volume Due to COVID-19 Than Any Other Specialty. Strata Decision Technology, https://eyewire.news/articles/analysis-55-percent-
fewer-americans-sought-hospital-care-in-march-april-due-to-covid-19 (18 June 2020).

15. Toro MD, Brézin AP, Burdon M, et al. Early impact of COVID-19 outbreak on eye care: insights from early impact of COVID-19 outbreak on eye care: insights from EUROCOVCAT group on eye care: insights from EUROCOVCAT group. *Eur J Ophthalmol* 2021; 31(1): 5–9. doi:10.1177/1120672120960339

16. Toro M, Choragiewicz T, Posarelli C, et al. European COVID-19 Cataract Group (#EUROCOVCAT). Early impact of COVID-19 outbreak on the availability of Cornea donors: warnings and recommendations. *Clin Ophthalmol* 2020; 14: 2879–2882.

17. Bangerter A. Treatment of amblyopia: part 1. *Strabismus* 2017; 25: 222–230.

18. Li T, Qureshi R and Taylor K. Conventional occlusion versus pharmacologic penalization for amblyopia. *Cochrane Database Syst Rev* 2019; 8: CD006460.

19. American Academy of Ophthalmology Pediatric Ophthalmology/ Strabismus_Panel. Preferred practice pattern® guidelines. *Amblyopia*. San Francisco, CA: American Academy of Ophthalmology, 2012, www.aao.org/pps.

20. Ciuffreda KJ, Levis DM and Selentow A. *Amblyopia: basic and clinical aspects*. Boston: Butterworth-Heinemann, 1991.

21. Levi DM. Visual processing in amblyopia: human studies. *Strabismus* 2006; 14: 11–19.

22. Ansons A and Davis H. Diagnosis and management of ocular motility disorders. 3rd ed. Oxford: Blackwell Science, 2001.

23. Holhos LB, Coroi MC, Holt G, et al. The burden of assessing ocular status of children - causes and control. *Maedica (Bucur)* 2020; 15: 391–393.

24. Gogate P, Gilbert C and Zin A. Severe visual impairment and blindness in infants: causes and opportunities for control. *Middle East Afr J Ophthalmol* 2011; 18: 109–114.

25. Sonksen PM and Dale N. Visual impairment in infancy: impact on neurodevelopmental and neurobiological processes. *Dev Med Child Neurol* 2002; 44: 782–791.

26. Dole KS, Deshpande AS, Deshpande MD, et al. Comparative evaluation of qualitative performance of technical human resource in school eye health program. *Indian J Ophthalmol* 2021; 69: 123–126.

27. Webber AL and Wood J. Amblyopia: prevalence, natural history, functional effects and treatment. *Clin Exp Optom* 2005; 88: 365–375.

28. Woodru BF, Hiscox F, Thompson JR, et al. Factors affecting the outcome of children treated for amblyopia. *Eye (London)* 1994; 8(Pt 6), 627–631.

29. Birch EE, Jost RM, Kelly KR, et al. Baseline and clinical factors associated with response to amblyopia treatment in a randomized clinical trial. *Optom Vis Sci* 2020; 97: 316–323.

30. Wang J, Li Y, Musch DC, et al. Progression of myopia in school-aged children after COVID-19 home confinement. *JAMA Ophthalmol* 2021; 139(3): 293–300. doi:10.1155/2020/4395278

31. Wong CW, Tsai A, Jonas JB, et al. Digital screen time during the COVID-19 pandemic: risk for a further myopia boom? *Am J Ophthalmol* 2020; 223: 333–337.

32. Mohan A, Sen P, Shah C, et al. Prevalence and risk factor assessment of digital eye strain among children using online e-learning during the COVID-19 pandemic: digital eye strain among kids (DESK study-1). *Indian J Ophthalmol* 2021; 69: 140–144.

33. Jayadev C, Sarbajna P and Vinekar A. Commentary: impact of the COVID-19 pandemic on digital eye strain in children. *Indian J Ophthalmol* 2020; 68: 2383–2384.

34. Dolgin E. The myopia boom. *Nature* 2015; 519: 276–278.

35. Xiang ZY and Zou HD. Recent epidemiology study data of myopia. *J Ophthalmol* 2020: 4395278.

36. Xu L, Ma Y, Yuan J, et al. COVID-19 quarantine reveals behavioral changes effect on myopia progression. *Ophthalmology*. 2021: S0161-6420(21)00257-8. doi:10.1016/j.jouphtha.2021.04.001

37. Maxwell J, Tong J and Schor CM. Short-term adaptation of accommodation, accommodative vergence and disparity vergence facility. *Vision Res* 2012; 62: 93–101.

38. Schuster AK, Krause L, Kuchenbäcker C, et al. Prevalence and time trends in myopia among children and adolescents. Results of the German KIGGS study. *Disch Arztebl Int* 2020; 117: 855–860.

39. Vagge A, Giannaccare G, Scarinci F, et al. Acute acquired concomitant esotropia from excessive application of near vision during the COVID-19 lockdown. *J Pediatr Ophthalmol Strabismus* 2020; 57: e88–e91.

40. Gifford KL, Richdale K, Kang P, et al. IMI – clinical management guidelines report. *Invest Ophthalmol Vis Sci* 2019; 60(3): M184–M203. doi:10.1167/iovs.18.23977

41. Tamez-Tamez VE and Ruiz-Lozano RE. Evaluating amblyopia during the era of COVID-19. *Graefes Arch Clin Exp Ophthalmol* 2020; 2: 1–3.

42. Speeg-Schatz C. Pediatric ophthalmology consultations during COVID-19 pandemic. *J Fr Ophthalmol* 2020; 43: 547.

43. Daruich A, Martin D and Bremond-Gignac D. Ocular manifestation as first sign of coronavirus disease 2019 (COVID-19): interest of telemedicine during the pandemic context. *J Fr Ophthalmol* 2020; 43: 389–391.

44. Burke BL Jr and Hall RW and Section on Telehealth Care. Telemedicine: pediatric applications. *Pediatrics* 2015; 136: e293–e308.

45. Lennnerstrand G, Kvannström G and Jakobsson P. Screening for visual and ocular disorders in children, evaluation of the system in Sweden. *Acta Paediatr* 1998; 87: 1173–1179.

46. Eibschitz-Tsimhoni M, Friedman T, Naor J, et al. Early screening for ambyogenic risk factors lowers the prevalence and severity of amblyopia. *J AAPOS* 2000; 4: 194–199.

47. Resnikoff S, Pascolini D, Mariotti SP, et al. Global magnitude of visual impairment caused by uncorrected refractive error in 2004. *Bull World Health Organ* 2008; 86: 63–70.

48. Hu H, Wu T, Fan L, et al. Knowledge of child health and affecting factors among preschool teachers: a cross-sectional study in Chongqing, China. *Risk Manag Healthc Policy* 2020; 13: 2515–2524.

49. Chung SA, Sitzer M, Prioli KM, et al. Reducing the costs of an eye care adherence program for underserved children referred through inner-city vision screenings. *Am J Ophthalmol* 2021; 227: 18–24. doi:10.1016/j.ajo.2021.02.012

50. Kapoor S, Eldib A, Hiasat J, et al. Developing a pediatric ophthalmology telemedicine program in the COVID-19 crisis. *J AAPOS* 2020; 24: 204–208. e2.